G1 Therapeutics, Inc. (GTHX)

G1 Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-47.97	-147.56	-148.35	-99.25	-122.45
Depreciation & Amortization	0.51	0.53	0.47	0.58	0.36
Share-Based Compensation	14.51	20.59	22.32	18.77	16.45
Other Operating Activities	-5.39	-2.18	-6.54	-3.84	6.07
Operating Cash Flow	-38.34	-128.62	-132.11	-83.74	-99.57
Capital Expenditures	0	-0.51	0	0.15	-2.72
Change in Investments	2.81	-50.02	0	0	0
Investing Cash Flow	2.81	-50.53	0	0.15	-2.72
Share Issuance / Repurchase	0.06	52.54	92.27	2.31	2.71
Debt Issued / Paid	-26.69	0	53.64	19.38	0
Other Financing Activities	-0.28	-0.04	-0.05	-	-
Financing Cash Flow	-26.91	52.5	145.86	21.69	2.71
Net Cash Flow	-62.44	-126.65	13.76	-61.9	-99.58
Free Cash Flow	-38.34	-129.13	-132.11	-83.59	-102.29
Free Cash Flow Margin	-46.46%	-251.70%	-419.71%	-184.59%	-
Free Cash Flow Per Share	-0.74	-2.96	-3.15	-2.21	-2.73

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).